Lung Cancer

Alecensa (alectinib) was granted approval by the Food and Drug Administration (FDA) to treat patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.

More patients with non-small cell lung cancer (NSCLC) should be evaluated and referred to clinical trials, especially those who may have molecular abnormalities, says Victoria M. Villaflor, M.D.

Sometimes patients with cancer need to adjust their thinking to change how they view their disease

Question: When do cancer scans shift from disease monitoring to routine checkups? Answer: You decide.

The approval is based on data from the phase 3 CheckMate-057 trial, in which second-line Opdivo reduced the risk of death by 28 percent versus docetaxel in patients with nonsquamous NSCLC.

The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.

Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.

The stage 4 lung cancer life twists and turns down a bumpy road, but it is a road that I am lucky enough to still be traveling.

To gain a patient's perspective on the Genomics of Young Lung Cancer Study and the importance of genomic testing, we spoke with Corey Wood, a 23-year-old trial participant and lung cancer survivor.

Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.

This is how my family and I were thrown into the cancer world.

Marianne Davies, from Smilow Cancer Hospital, Yale School of Nursing, provides an overview of immunotherapy-related side effects that patient with lung cancer may experience.

At an 18-month analysis, the overall survival rate with the PD-1 inhibitor was 28 percent versus 13 percent with docetaxel in previously treated patients with squamous NSCLC.